---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288611636.md"
description: "TransCode Therapeutics shares are trading lower. The company announced Phase 1a dose escalation clinical trial update showing safety, tolerability, and disease stabilization with its lead candidate TTX-MC138."
datetime: "2026-06-03T16:57:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288611636.md)
  - [en](https://longbridge.com/en/news/288611636.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288611636.md)
---

# 

TransCode Therapeutics shares are trading lower. The company announced Phase 1a dose escalation clinical trial update showing safety, tolerability, and disease stabilization with its lead candidate TTX-MC138.

### Related Stocks

- [RNAZ.US](https://longbridge.com/en/quote/RNAZ.US.md)

## Related News & Research

- [TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | RNAZ Stock News](https://longbridge.com/en/news/289052490.md)
- [Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch](https://longbridge.com/en/news/289404778.md)